Next-Generation Lacrimal System for Targeted and Controlled Drug Delivery
Legal Citation
Summary of the Inventive Concept
A revolutionary lacrimal system that leverages cutting-edge technologies to provide targeted, controlled, and sustained drug delivery to the eye, overcoming limitations of existing systems.
Background and Problem Solved
Current lacrimal systems for drug delivery face challenges in achieving precise control over drug release, leading to inadequate treatment outcomes. The original patent's lacrimal system, while innovative, has limitations in terms of controlled release and targeted delivery. The new inventive concept addresses these limitations by incorporating advanced technologies, such as MEMS-based pumps, micro-needle arrays, and nanotechnology-based targeted delivery systems.
Detailed Description of the Inventive Concept
The next-generation lacrimal system comprises a self-sustaining, bio-compatible implantable reservoir device with a porous surface for controlled release of therapeutic agents. The system can also include a wearable, miniaturized, and flexible device with a micro-needle array for trans-scleral delivery or a smart contact lens with a micro-reservoir and micro-pump for controlled release. Additionally, the system can utilize nanotechnology-based targeted drug delivery systems, comprising nanoparticles loaded with therapeutic agents and targeted to specific cells or tissues in the eye. These components work in tandem to provide precise control over drug release, ensuring optimal treatment outcomes.
Novelty and Inventive Step
The new claims introduce significant advancements in controlled release and targeted delivery, overcoming the limitations of the original patent. The incorporation of MEMS-based pumps, micro-needle arrays, and nanotechnology-based targeted delivery systems provides a novel and non-obvious solution for lacrimal system-based drug delivery.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of bio-absorbable materials, wireless communication for real-time monitoring, or integration with artificial intelligence for personalized treatment. Variations could include adapting the system for delivery of other therapeutic agents, such as gene therapy or stem cells, or for use in other ocular diseases or disorders.
Potential Commercial Applications and Market
The next-generation lacrimal system has vast commercial potential in the ophthalmic industry, with applications in treating a range of ocular diseases and disorders, including glaucoma, dry eye, and age-related macular degeneration. The system's targeted and controlled delivery capabilities make it an attractive solution for pharmaceutical companies and healthcare providers seeking to improve treatment outcomes and reduce healthcare costs.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61F9/00772 |
| A | A61 | A61F9/0017 |
| A | A61 | A61M37/00 |
| A | A61 | A61M31/002 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medical device engineering focused on ophthalmic drug delivery systems, specifically lacrimal system interventions involving controlled release mechanisms, micro-engineering, and targeted therapeutic delivery technologies
Person of Ordinary Skill (PHOSITA) Profile
A biomedical engineer or medical device designer with expertise in microfluidics, drug delivery systems, nanotechnology, and implantable medical devices, holding advanced degrees in bioengineering or medical technology with 3-5 years of specialized experience
Obviousness Rationale
A PHOSITA would recognize that the published technical disclosure represents predictable variations on the source patent's fundamental lacrimal drug delivery system by applying known micro-engineering and nanotechnology techniques to enhance controlled drug release. The modifications represent logical extensions of the original patent's core concept of targeted ocular drug delivery, utilizing standard design approaches in medical device engineering to improve precision, duration, and targeting of therapeutic agents.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,461 |
|---|---|
| Title | Lacrimal system for drug delivery |
| Assignee(s) | The Regents of the University of Colorado, a body corporate |